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Abstract
Purpose Response evaluation in patients with glioblastoma after chemoradiotherapy is challenging due to progressive, contrast-
enhancing lesions on MRI that do not reflect true tumour progression. In this study, we prospectively evaluated the ability of the
PET tracer 18F-fluorothymidine (FLT), a tracer reflecting proliferative activity, to discriminate between true progression and
pseudoprogression in newly diagnosed glioblastoma patients treated with chemoradiotherapy.
Methods FLT PETandMRI scans were performed before and 4 weeks after chemoradiotherapy. MRI scans were also performed
after three cycles of adjuvant temozolomide. Pseudoprogression was defined as progressive disease on MRI after chemoradio-
therapy with stabilisation or reduction of contrast-enhanced lesions after three cycles of temozolomide, and was compared with
the disease course during long-term follow-up. Changes in maximum standardized uptake value (SUVmax) and tumour-to-normal
uptake ratios were calculated for FLT and are presented as the mean SUVmax for multiple lesions.
Results Between 2009 and 2012, 30 patients were included. Of 24 evaluable patients, 7 showed pseudoprogression and 7 had
true progression as defined by MRI response. FLT PET parameters did not significantly differ between patients with true
progression and pseudoprogression defined byMRI. The correlation between change in SUVmax and survival (p = 0.059) almost
reached the standard level of statistical significance. Lower baseline FLT PET uptake was significantly correlated with improved
survival (p = 0.022).
Conclusion Baseline FLT uptake appears to be predictive of overall survival. Furthermore, changes in SUVmax over time showed
a tendency to be associated with improved survival. However, further studies are necessary to investigate the ability of FLT PET
imaging to discriminate between true progression and pseudoprogression in patients with glioblastoma.
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Introduction
Glioblastoma (GBM) is the most common and most ag-
gressive primary brain tumour. It accounts for more than
50% of all gliomas and has an incidence rate of 3.19 per
100.000 in the United States [1]. Current first-line treat-
ment, consisting of maximal surgical resection followed
by postoperative radiation with concomitant and adjuvant
temozolomide (TMZ) therapy, has improved 2-year sur-
vival from 11% to 27% and 5-year survival from 2% to
10% [2]. However, response evaluation of this treatment
in these patients is problematic because of the difficulty in
distinguishing recurrent tumour (i.e. true progression)
from pseudoprogression. Pseudoprogression is defined as
progressive gadolinium-enhanced lesions on MRI imme-
diately after the end of concurrent chemoradiotherapy,
following stabilisation or spontaneous improvement in
the contrast-enhanced lesions without further treatment
other than adjuvant TMZ [3, 4]. This is observed in 28–
66% of all GBM patients undergoing chemoradiotherapy,
and primarily occurs within the first 3 months after com-
pletion of chemoradiotherapy [5]. The difficulty in
distinguishing true progression from pseudoprogression
impedes clinical decision making in these patients. In pa-
tients with pseudoprogression, standard treatment with ad-
juvant TMZ should be continued, whereas in patients with
true tumour progression, other treatment modalities – al-
though scarce – or palliative supportive care are more
appropriate.
The use of several amino acid tracers, including 11C-methi-
onine (MET), 18F-fluoroethyl-L-tyrosine (FET) and L-3,4-di-
hydroxy-6-18F-fluorophenylalanine (F-DOPA), for the meta-
bolic imaging of brain tumours has been extensively explored
[6–9]. Imaging studies with these amino acid tracers have
provided valuable information on the identification of
nonenhancing, metabolically active tumour areas, and
the prediction of treatment response in patients receiving
antiangiogenic therapy [10–12].
Interestingly, 18F-fluorothymidine (FLT) is an 18F-labelled
thymidine analogue that is taken up preferentially by prolifer-
ating cells. FLT tracer uptake reflects thymidine kinase 1 ac-
tivity, which is involved in DNA synthesis, and can be used as
a measure of cell proliferation. In several tumour types, FLT
uptake measured with PET corresponds to the Ki67 prolifera-
tion index, and its change is correlated with response to ther-
apy [13, 14].
In glioma patients, FLT uptake has been used for tu-
mour grading and is correlated with Ki67 proliferation
index [15, 16]. Moreover, FLT PET has been found to
perform better in predicting survival and recurrence in
glioma patients than FDG PET and MRI [17, 18].
However, to date, no prospective study has been conduct-
ed to determine the ability of FLT PET to discriminate
between pseudoprogression and true progression.
Therefore, the aim of this prospective study in patients
with newly diagnosed GBM was to determine whether
FLT PET scans, performed before and after chemoradio-
therapy, can discriminate between true progression and
pseudoprogression as measured by MRI after three
courses of adjuvant TMZ. In addition, MRI responses
were compared and verified in relation to the disease
course during long-term follow-up.
Materials and methods
Patients and treatment
Patients with newly diagnosed GBM or gliosarcoma (WHO
grade IV, hereafter referred to as GBM) who were eligible for
standard treatment with radiotherapy and TMZ were pro-
spectively included. After surgical resection or biopsy, pa-
tients were treated with radiotherapy consisting of 2 Gy
irradiation 5 out of 7 days per week for 6 weeks, for a total
dose of 60 Gy. Patients received concomitant TMZ orally
at a dose of 75 mg/m2 daily for 6 weeks. After a treatment
break of 4 weeks, patients received up to six cycles of
adjuvant TMZ (150–200 mg/m2) for 5 days every 28 days.
The use of corticosteroids during treatment was recorded. No
changes in treatment were introduced based on the results of
the FLT PET scan. Overall survival was calculated from the
date of informed consent to the date of death or last known
date alive, censored at the time of analysis (end of December
2017). Written informed consent was obtained from all indi-
vidual participants included in the study. The protocol was
approved by the local medical ethics committee and registered
with the Dutch trial register (NTR3680).
MRI imaging
Patients underwent standard radiological follow-up with MRI
(1.5 T using T1, T2 and contrast-enhanced 3D T1 gradient
echo sequences) within 72 h of surgery (baseline), 10 weeks
after the start of treatment (4 weeks after completing chemo-
radiotherapy), 22 weeks after the start of treatment (after the
third cycle of adjuvant TMZ or earlier as clinically indicated),
and every 3 months thereafter. MRI data for this study were
assessed by an independent neuroradiologist and a radiologist-
in-training using the Macdonald criteria for tumour response
evaluation [19]. Pseudoprogression was defined as progres-
sive disease on MRI at 10 weeks, with stabilisation or reduc-
tion in enhancing lesions on MRI at 22 weeks. True progres-
sion was defined as progressive disease on MRI at both
10 weeks and 22 weeks. The MRI responses were confirmed
in relation to the disease course during long-term survival
follow-up of these patients.
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FLT PET imaging
FLT was synthesized as described by Been et al. [20]. FLT
PETscans were performed after surgery, but before the start of
radiotherapy (baseline) and 10 weeks after the start of treat-
ment (4 weeks after completing chemoradiotherapy). Patients
were instructed to fast for a minimum of 4 h before intrave-
nous injection of tracer. For FLT, 200 MBq was administered
30 min before the baseline PET scan (mean ± SD 201.22 ±
14.16 MBq) and follow-up scan (mean ± SD 196.60 ±
26.70 MBq). A 60-min dynamic protocol was used in the first
three patients to determine the optimal timing, followed by an
abbreviated, static protocol of 30 min in the remaining pa-
tients. PET scans were performed on either an HR+ ECAT
Exact or an mCT PET scanner (Siemens, Knoxville, TN).
Baseline and follow-up PET scans were performed on the
same scanner in almost all patients. Both the ECAT Exact
and mCT PET scanners were standardized according to
The Netherlands protocol for standardization and quantifica-
tion of FDG whole-body PET studies in multicentre trials,
which ultimately formed the foundation for the European
Association of Nuclear Medicine (EANM) procedure guide-
lines for tumour PET imaging [21–23].
The maximum standardized uptake value (SUVmax) was
assessed according to EANM procedure guidelines by draw-
ing a region of interest (ROI) around every lesion on a sepa-
rate reconstruction [22]. For multiple lesions, the mean
SUVmax was calculated. FLT PET scans were fused with the
most recent MRI scan to differentiate actual tumour from
postsurgery effects outside the cerebrum if needed. The
SUVmean for normal brain tissue was assessed by drawing a
ROI in the contralateral brain tissue. Tumour and nontumour
ROIs were drawn by the same clinical researcher and were
confirmed by a nuclear medicine physician. Tumour-to-
normal (T/N) ratios were determined by dividing the
SUVmax of the tumour by the SUVmean of the normal brain
tissue. Threshold values for SUVmax and T/N ratio, and a FLT
PET response, defined as a 25% decrease in SUVmax between
the first and second FLT PETscan, were based on correspond-
ing FLT studies in the literature [18, 24, 25].
Ki67 immunohistochemical staining
Deparaffinized GBM tissue from primary surgery or biopsy
was used to evaluate the proliferation fraction of tumour cells
(tissue slices of thickness 4 μm). Antigen retrieval was per-
formed using 10mMTris/1 mMEDTA (pH 9) in a microwave
at 700 W. Endogenous peroxidase and biotin were blocked
using routine techniques. The slides were incubated with the
primary antibody, Ki67 (clone MIB-1; Dako, Glostrup,
Denmark) at room temperature for 1 h, followed by applica-
tion of the secondary antibody, peroxidase-conjugated rabbit
anti-mouse serum (Dako), and the tertiary antibody,
peroxidase-conjugated goat anti-rabbit serum (Dako), for
30 min each. The first antibody was diluted 1/100 in 1%
bovine serum albumin (BSA)/phosphate-buffered saline
(PBS). The secondary and tertiary antibodies were diluted 1/
100 in 1% BSA/PBS with 1% AB serum. Colour was devel-
oped with 3,3′-diaminobenzidine (Sigma, Zwijndrecht,
The Netherlands) for 10 min. The slides were scanned for
hot spots of proliferative activity. In one high-power field
(×400 magnification) the fraction of Ki67-positive nuclei/
total number of nuclei was determined.
Statistics
Taal et al. found that 18 of 85 patients (20%) had discordant
MRI scans showing disease progression on the first follow-up
scan 4 weeks after the end of radiotherapy followed by
stabilisation or a reduction in the contrast-enhanced lesions on
MRI at 22weeks, indicating pseudoprogression [3].McNemar’s
test showed that five discordant MRI scans in the absence of
discordant FLT PET scans would be sufficient to prove the
superiority of FLT PET over MRI for discriminating between
true progression and pseudoprogression. Based on these as-
sumptions, at least 25 patients were needed for this study.
An independent samples t test and the Mann–WhitneyU test
were used to compare FLT uptake and T/N ratios, respectively,
between patients with and without pseudoprogression. To dis-
criminate between true progression and pseudoprogression, re-
ceiver operating characteristic curves were used to find an opti-
mal cut-off value for FLTuptake and changes in uptake. Fisher’s
exact test was used to determine if FLT PET could accurately
identify patients with pseudoprogression, based on optimal cut-
off values. Kaplan-Meier curveswith the log-rank test were used
to analyse survival in our long-term survival follow-up. An ad-
ditional multiple Cox regression analysis was performed on sur-
vival data to correct for clinical variables (i.e. tumour extent and
size, steroid use and Ki67 proliferation index). Furthermore,
hazard ratios (HRs) for clinical variables were calculated and
are reported with 95% confidence intervals (CIs). Lastly, a
Pearson correlation test was used to calculate correlations be-
tween FLT uptake and proliferation index. A two-sided p value
of <0.05 was considered significant. Statistics were calculated
using IBM SPSS Statistics 22. Graphs were generated using
GraphPad Prism version 7.02 for Windows.
Results
Patients
Of 30 patients (28 with GBM and 2 with gliosarcoma, WHO
grade IV) included between November 2009 and November
2012 (Table 1), five were not evaluable for pseudoprogression
due to early death, salvage surgery or clinical deterioration
Eur J Nucl Med Mol Imaging
that prevented further participation in the study, and one was
excluded from the pseudoprogression analysis as only a base-
line MRI scan before tumour resection was available. The
CONSORT diagram is shown in Fig. 1.
Baseline FLT PET scans were performed 4.9 ± 3.8 days
before the start of radiotherapy, except in two patients
who had their baseline FLT PET scan 2 and 4 days after
the start of radiotherapy for logistic reasons. Follow-up
FLT PET scans were performed 27.0 ± 8.0 days after com-
pletion of radiotherapy. Three patients had their follow-up
FLT PET scan 1 day after the start of adjuvant TMZ.
Finally, for logistic reasons two patients had their FLT
PET scan 6 and 22 days after the start of adjuvant TMZ,
respectively.
Pseudoprogression as defined by MRI response
A total of 24 patients were analysed for pseudoprogression
(Fig. 1). The mean SUVmax values at baseline and at 10 weeks
in these 24 patients were 1.96 ± 1.00 and 1.28 ± 0.53, respec-
tively. Pseudoprogression was observed in seven patients, and
true progression in seven other patients (Fig. 2). Ten patients
had either stable disease or a complete response on MRI after
10 weeks (Table 2). Six patients, of whom one had
pseudoprogression and another had true progression, initially
showed no baseline FLT uptake due to a macroscopic gross
total resection of their tumour. Therefore, some of the
pseudoprogression analyses had to be performed in the re-
maining patients.
Patients with pseudoprogression had mean SUVmax
values of 2.01 ± 1.08 at baseline and 1.41 ± 0.65 at
10 weeks, compared with 2.07 ± 1.11 at baseline and
1.28 ± 0.62 at 10 weeks in patients with true progression.
There was no significant difference between patients with
pseudoprogression and those with true progression in
SUVmax at baseline (p = 0.928), SUVmax at 10 weeks
(p = 0.699), change in SUVmax (p = 0.567) and T/N ratio
(p = 0.699) on FLT PET scans. Furthermore, FLT parame-
ters in patients with pseudoprogression and those with true
progression did not significantly differ from the FLT pa-
rameters in patients with stable disease or complete
response.
Two of the patients with pseudoprogression were identified
based on FLT uptake reduction, while three patients with true
progression also showed a decrease in SUVmax of more than
25% (sensitivity 29%, specificity 43%). Furthermore, cut-off
values identified as optimal by others for identifying recurrent
tumour with a SUV of ≥1.34 and a T/N ratio of ≥4.94 were
applied to FLT PET scans at 10 weeks [24, 25]. However, this
approach did not provide an accurate prediction in all patients.
Table 1 Patient characteristics
Characteristic Value















aOf 27 patients available for analysis
Fig. 1 CONSORT diagram
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ROC curves showed no other reasonable cut-off value for any
parameter.
Long-term follow-up
In all 30 patients, a baseline FLT PET scan was avail-
able. However, five patients showed no FLT uptake on
baseline FLT PET. Therefore, survival analyses with
SUVmax at baseline were based on 25 patients. At the
end of December 2017, 27 patients had died and three
were censored at the date last known to be alive. The
median overall survival in all patients was 14.1 months
(95% CI 3.4–24.8 months).
SUVmax at baseline and 10 weeks were both significantly
correlated with survival (HR = 3.03, 95% CI 1.72–5.33. p <
0.001, and HR = 5.16, 95% CI 1.83–14.55, p = 0.002, respec-
tively). The correlation between change in SUVmax
(ΔSUVmax) and survival almost reached the standard level of
statistical significance (HR = 0.44, 95% CI 0.19–1.03, p =
0.059). When compared to the response defined by MRI after
three cycles of adjuvant TMZ, MRI response was more sig-
nificantly associated with survival (p = 0.028) than SUVmax at
baseline (p = 0.048) and at follow-up (p = 0.044).
Furthermore, use of steroids, tumour size and extent of
disease were significantly associated with survival (p =
0.007, p = 0.001 and p = 0.047, respectively). After correction
for these clinical variables, SUVmax at baseline remained sig-
nificantly correlated with survival (HR = 6.82, 95% CI 1.31–
35.42, p = 0.022; Table 3). Furthermore, the results of the
subgroup analysis, excluding six patients who were scanned
during radiotherapy or TMZ treatment, were comparable to
those of the main analysis.
Proliferation index
In the 28 patients with specimens available for Ki67 staining,
the mean SUVmax at baseline and at 10 weeks, and ΔSUVmax
did not correlate with the Ki67 index of the tumour tissue
before treatment (r = 0.233, p = 0.285; r = −0.321, p = 0.145;
and r = −0.191, p = 0.420, respectively).
Discussion
In this small, prospective trial, we defined pseudoprogression
and true progression based on both MRI scans, and compared
MRI responses with the disease course during long-term fol-
low-up. Changes in SUVmax (ΔSUVmax) between the FLT PET
scan at baseline and 10weeks did not discriminate between true
progression and pseudoprogression as defined by MRI.
Interestingly, during long-term follow-up, ΔSUVmax between
baseline and 10 weeks showed a tendency to be associated with
improved survival. Furthermore, in the 24 patients included in
our analysis, a lower baseline FLTuptake did not correlate with
Ki67 index, but was predictive of a longer survival.
Despite the urgent need to distinguish between true pro-
gression and pseudoprogression in GBM patients, this is one
of the few prospective studies that has assessed the ability of
FLT PET imaging to distinguish pseudoprogression from true
progression with long-term follow-up [26]. To date, mainly
retrospective studies have been performed in patients with
radiological suspicion of recurrent brain tumour at different
time points, and these have shown variable results. In one
study, FLT PET had a low specificity for distinguishing
Fig . 2 MRI and FLT PET imaging in a pat ient with (a )
pseudoprogression and (b) true progression: top row: MRI images at
baseline (left), 10 weeks (centre) and 22 weeks (right); bottom row:
PET images at baseline (left) and 10 weeks (right). FLT PET images
showed a SUVmax of 1.44 at baseline and 0.74 at 10 weeks in the
patient with pseudoprogression, and 3.70 at baseline and 1.80 at
10 weeks in the patient with true progression
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recurrent tumour from benign lesions in 20 patients [25].
Three other studies were able to discriminate between true
progression and radionecrosis in 15, 19 and 21 glioma
patients, respectively, using FLT kinetic values and the T/
N ratio [24, 27, 28].
MRI is still considered the optimal modality for the assess-
ment of treatment response and effects [3]. Consequently,
changes on MRI at 10 and 22 weeks were used in our study
to define pseudoprogression and true progression.
Unfortunately, at the time of this study, the RANO criteria
for glioma response evaluation on MRI were still under de-
velopment, and therefore, the MacDonald criteria were used
instead. As well as the imaging characteristics on convention-
al contrast-enhanced T1-weighted MRI images, the RANO
response criteria also include characteristics on T2-weighted
and fluid-attenuated inversion recovery (FLAIR) images [29].
However, due to the difficulty in identifying tumour lesions
without contrast enhancement and the quantitative evaluation
of the degree of T2/FLAIR changes to define tumour progres-
sion, an adequate assessment of treatment response or tumour
recurrence with the help of the RANO criteria remains prob-
lematic [30, 31].
A key limitation of FLT, in contrast to MET, FET and F-
DOPA amino acid tracers, is that FLT uptake is primarily




















Pseudoprogression 3 NU ND 0.81 3.1 ND PD SD 35 31.9
4a 1.73 5.6 1.58 6.3 −8.7 PD SD 35 16.8
14 1.23 3.0 1.14 3.5 −7.3 PD SD 60 45.3
15 1.90 5.3 1.61 4.0 −15.3 PD SD 18 9.5
18 4.17 8.7 2.67 3.3 −36.0 PD SD ND 9.4
25 1.61 6.0 1.33 3.9 −17.4 PD SD 50 41.2
28 1.44 7.6 0.74 4.1 −48.6 PD SD 50 50.2c
Progressive
disease
8 2.18 14.5 0.74 4.4 −66.1 PD PD 50 19.3
13 NU ND 0.96 1.7 ND PD PD 25 8.8
20 1.38 3.9 1.68 2.8 21.7 PD PD 30 11.3
21 1.59 5.9 0.85 2.3 −46.5 PD PD 25 59.4c
22a,b 0.65 2.0 0.68 2.7 4.6 PD PD 20 13.6
27 3.70 9.5 1.80 5.3 −51.4 PD PD 50 5.9
29 2.93 8.1 2.23 5.9 −23.9 PD PD 7 7.5
Other 2 NU ND NU ND ND SD SD 40 40.3
5 1.24 3.1 1.46 3.2 17.7 SD PD 40 19.7
6a 1.75 4.4 0.95 2.9 −45.7 SD SD 30 31.2
9 2.43 6.2 1.14 2.5 −53.1 SD SD 30 24.0
10 NU ND NU ND ND CR PD 10 14.1
11a NU ND NU ND ND CR CR 50 28.4
16 3.00 5.9 1.26 2.6 −58.0 SD PD 19 9.7
19 1.10 2.0 1.00 1.9 −9.1 SD SD 40 62.2c
23a,b 0.35 1.5 NU ND ND CR CR 15 19.4
26 2.85 16.8 0.93 5.5 −67.4 SD PD 60 6.4
Excluded from
analysis
1 1.55 3.4 1.33 2.8 −14.2 NE SD 30 29.0
7 1.59 7.6 1.34 8.4 −15.7 PD PD 25 10.0
12a 2.84 9.8 1.64 5.1 −42.3 SD ND 30 4.1
17 5.02 9.0 ND ND ND ND ND 50 1.3
24 1.64 6.6 ND ND ND SD ND 20 8.7
30 1.42 3.3 ND ND ND SD SD ND 10.6
CR complete response, PD progressive disease, SD stable disease, ND not done, NE not evaluable, NU no uptake
a Patient underwent follow-up FLT PET during adjuvant temozolomide treatment (range 1–22 days)
b Patient underwent baseline FLT PET during radiotherapy (range 2–4 days)
c Patient censored at date last known alive
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restricted to contrast-enhancing tumour lesions due to its de-
pendence on the permeability and tumour disruption of the
blood–brain barrier [31, 32]. Therefore, the inability to accu-
rately discriminate between true progression and
pseudoprogression in our prospective study with FLT PET
may well have been due to the fact that FLT uptake in high-
grade gliomas reflects not only trapping of FLT in proliferat-
ing tumour cells, but also disruption of the blood–brain barrier
[33]. As a result, areas showing true progression as well as
pseudoprogression would show an increased FLT uptake.
An important limitation of this study is that only SUVmax
was used for quantification of FLT uptake. The use of SUVmax
does not take into account the heterogeneity in FLT uptake.
Therefore, kinetic analysis might be of interest to distinguish
between FLT uptake due to proliferation and FLT leakage that
results from disruption of the blood–brain barrier, as shown in
previous studies [33–36]. In addition, kinetic analysis would
support the correct interpretation of the static FLT data.
Unfortunately, kinetic analysis could not be performed in the
present study, as FLT PET scans were performed 30 min after
tracer injection. However, SUVmax is easy to obtain, is mostly
used in clinical practice with FDG PET imaging, and has been
proven to be robust. In glioma, SUVmax quantification of FLT
uptake has a repeatability coefficient of 23%, which seems to
be better than corresponding values for FDG PET [37, 38].
Furthermore, in other studies FLT kinetic values have been
found to be well correlated with SUV parameters [39, 40].
Several studies have suggested other parameters for
quantification of FLT PET, such as proliferative volume and
parametric response maps [12, 41]. Due to the small numbers
of patients and the different approaches used for quantifica-
tion, direct comparison of the results is difficult.
Lastly, it is difficult to determine the optimal timing of
serial FLT PET imaging before and during GBM treatment.
Since the aim of this study was to differentiate between true
progression and pseudoprogression after chemoradiotherapy,
the baseline FLT PET scan was performed after surgery.
Imaging before surgery would have revealed tumour uptake,
but most patients undergo a gross total resection of tumour
tissue. However, imaging after surgery can also lead to in-
creased FLT uptake due to increased blood flow and prolifer-
ation as part of the wound healing process. This might also
explain the lack of correlation between FLT uptake and the
Ki67 index in our study, in contrast to the results of previous
studies, in which the FLT PET scans were often performed
before surgery [15–17].
Interestingly, FLT PET uptake at baseline and at 10 weeks
was significantly correlated with survival. Furthermore, a de-
crease in FLT uptake over time also showed a tendency to be
associated with improved survival (p = 0.059). After correc-
tion for clinical variables, only baseline FLT uptake remained
significantly associated with survival. However, previous
studies have also confirmed that (change in) FLT uptake is a
strong independent predictor of survival [12, 18, 42]. This is in
line with the results of imaging studies using FET and F-
DOPA amino acid PET tracers [11, 12]. Therefore, FLT
Table 3 Univariate and
multivariate survival analyses No. of events/no.
of patients
Hazard ratio (95% CI) p value
Univariate analysis
SUVmax at baseline – 3.03 (1.72–5.33) <0.001
SUVmax at 10 weeks – 5.16 (1.83–14.55) 0.002
ΔSUVmax – 0.44 (0.19–1.03) 0.059
Use of steroids No 8/10 1 0.007
Yes 19/20 3.21 (1.37–7.53)
Tumour size (mm2) – 1.00 (1.000–1.001) 0.001
Tumour extent Single lobe 19/22 1 0.047
Multiple lobes 8/8 2.37 (1.01–5.55)
Ki67 (%) – 0.97 (0.94–1.01) 0.095
Multivariate analysis
SUVmax at baseline – 6.82 (1.31–35.42) 0.022
SUVmax at 10 weeks – 5.01 (0.62–40.56) 0.131
ΔSUVmax – 0.42 (0.12–1.45) 0.170
Use of steroids No 8/10 1 0.554
Yes 19/20 1.50 (0.39–5.70)
Tumour size (mm2) – 1.00 (1.000–1.004) 0.011
Tumour extent Single lobe 19/22 1 0.022
Multiple lobes 8/8 18.38 (1.54–219.96)
Ki67 (%) – 1.01 (0.97–1.06) 0.595
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uptake may still provide useful prognostic information in pa-
tients with GBM.
Conclusion
Our study suggests that further evaluation of FLT PET imag-
ing is warranted to define its ability to discriminate between
pseudoprogression and true progression in GBM patients
treated with chemoradiotherapy, as this remains an urgent un-
met need.
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